Literature DB >> 2978961

Megakaryoblastic leukemia and Down's syndrome: a review.

A Zipursky1, M Peeters, A Poon.   

Abstract

Megakaryoblastic leukemia and transient leukemia in Down's syndrome have been reviewed using case reports from the literature and our own experience at the Hospital for Sick Children. The following conclusions have been reached: (1) approximately 20% of leukemia (excluding transient leukemia) in Down's syndrome is acute megakaryoblastic leukemia; (2) approximately 20% of all leukemia in Down's syndrome is transient leukemia; (3) transient leukemia in Down's syndrome is acute megakaryoblastic leukemia; (4) recurrence of acute megakaryoblastic leukemia occurs in 20% of the cases of transient leukemia; and (5) the incidence of acute megakaryoblastic leukemia in Down's syndrome is estimated to be 400 times that in normal children. These observations suggest that a specific form of leukemia, namely acute megakaryoblastic leukemia, has a remarkable association with Down's syndrome.

Entities:  

Mesh:

Year:  1987        PMID: 2978961     DOI: 10.3109/08880018709141272

Source DB:  PubMed          Journal:  Pediatr Hematol Oncol        ISSN: 0888-0018            Impact factor:   1.969


  11 in total

1.  A regulatory interplay between miR-27a and Runx1 during megakaryopoiesis.

Authors:  Oren Ben-Ami; Niv Pencovich; Joseph Lotem; Ditsa Levanon; Yoram Groner
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-29       Impact factor: 11.205

2.  Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children's Oncology Group Study A2971.

Authors:  Alan S Gamis; Todd A Alonzo; Robert B Gerbing; Joanne M Hilden; April D Sorrell; Mukta Sharma; Thomas W Loew; Robert J Arceci; Dorothy Barnard; John Doyle; Gita Massey; John Perentesis; Yaddanapudi Ravindranath; Jeffrey Taub; Franklin O Smith
Journal:  Blood       Date:  2011-08-17       Impact factor: 22.113

3.  Isolation of a cosmid clone corresponding to an inv(21) breakpoint of a patient with transient abnormal myelopoiesis.

Authors:  T Ohta; M Nakano; T Tsujita; K Abe; K Osoegawa; T Yamagata; K Yoshiura; Y Jinno; E Soeda; Y Nakamura; N Niikawa
Journal:  Am J Hum Genet       Date:  1996-03       Impact factor: 11.025

4.  Congenital abnormalities and acute leukemia among children with Down syndrome: a Children's Oncology Group study.

Authors:  Amy M Linabery; Cindy K Blair; Alan S Gamis; Andrew F Olshan; Nyla A Heerema; Julie A Ross
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-09-30       Impact factor: 4.254

5.  Cytogenetic and molecular studies of Down syndrome individuals with leukemia.

Authors:  J J Shen; B J Williams; A Zipursky; J Doyle; S L Sherman; P A Jacobs; A L Shugar; S W Soukup; T J Hassold
Journal:  Am J Hum Genet       Date:  1995-04       Impact factor: 11.025

6.  Developmental differences in IFN signaling affect GATA1s-induced megakaryocyte hyperproliferation.

Authors:  Andrew J Woo; Karen Wieland; Hui Huang; Thomas E Akie; Taylor Piers; Jonghwan Kim; Alan B Cantor
Journal:  J Clin Invest       Date:  2013-07-01       Impact factor: 14.808

7.  Molecular pathways: induction of polyploidy as a novel differentiation therapy for leukemia.

Authors:  Diane S Krause; John D Crispino
Journal:  Clin Cancer Res       Date:  2013-08-20       Impact factor: 12.531

8.  Mosaic Trisomy 21 and Trisomy 14 as Acquired Cytogenetic Abnormalities without GATA1 Mutation in A Pediatric Non-Down Syndrome Acute Megakaryoblastic Leukemia.

Authors:  Yi Xiao; Jia Wei; Jin-Huan Xu; Jian-Feng Zhou; Yi-Cheng Zhang
Journal:  Chin J Cancer Res       Date:  2011-09       Impact factor: 5.087

9.  Chromosomal rearrangement in Down syndrome with acute myeloid leukemia.

Authors:  Chetana Bakshi; Pratibha Amare Kadam; Dhiraj Abhyankar; Chanda Baisane; Shripad Banavali; Suresh Advani
Journal:  Indian J Pediatr       Date:  2003-09       Impact factor: 1.967

10.  Leukemia Risk in a Cohort of 3.9 Million Children with and without Down Syndrome.

Authors:  Emily C Marlow; Jonathan Ducore; Marilyn L Kwan; Stephanie Y Cheng; Erin J A Bowles; Robert T Greenlee; Jason D Pole; Alanna Kulchak Rahm; Natasha K Stout; Sheila Weinmann; Rebecca Smith-Bindman; Diana L Miglioretti
Journal:  J Pediatr       Date:  2021-03-06       Impact factor: 6.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.